The financing seems counter to all the bullish thoughts about TRIL potential. I understand their need for the money but this seems like a CEO/CFO fumble or an acknowledgement of their poor chances of success with trials. Neither one good.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.